Company / R&D Expense
Annovis Bio, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$25.2M
FY2025
5-year range
$3.1M / $38.8M
FY2021-FY2025
Trend
-35.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $17M to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of +100.6%.
Improved from $17M to $25M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +15.1%
- 5-Year CAGR
- +100.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +100.6%, indicating consistent growth.
- In FY2025, r&d expense decreased 35.0% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.2M | -35.0% |
| FY2024 | $38.8M | +134.9% |
| FY2023 | $16.5M | +0.0% |
| FY2022 | $16.5M | +440.8% |
| FY2021 | $3.1M | +293.4% |
| FY2020 | $776.3K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026